Mammography Screening Reveals Limited Effect on Breast Cancer Mortality in Swedish Study

The study’s findings were published July 17, 2012, in the Journal of the National Cancer Institute. Since 1974, Swedish women aged 40-69 have increasingly been offered mammography screening, with nationwide coverage peaking in 1997. The investigators’ goal was to figure out if mortality trends would be reflected accordingly.

In order to determine this, Philippe Autier, MD, of the International Prevention Research Institute (iPRI; Nimes, France), and colleagues, looked at data from the Swedish Board of Health and Welfare from 1960-2009 to analyze trends in breast cancer mortality in women aged 40 and older by the county in which they lived. The researchers compared actual mortality trends with the theoretic outcomes using models in which screening would result in mortality reductions of 10%, 20%, and 30%.

The researchers expected that screening would be associated with a gradual reduction in mortality, especially because Swedish mammography trials and observational studies have suggested that mammography leads to a reduction in breast cancer mortality. In this researcher, however, they discovered that breast cancer mortality rates in Swedish women started to decrease in 1972, before the initiation of mammography, and have continued to drop at a rate similar to that in the prescreening period. “It seems paradoxical that the downward trends in breast cancer mortality in Sweden have evolved practically as if screening had never existed,” they stated in their study “Swedish breast cancer mortality statistics are consistent with studies that show limited or no impact of screening on mortality from breast cancer.”

The researchers noted specific limitations of their study--specifically, that it was observational, so unable to take into account the potential impact of other breast cancer risk factors such as obesity, which may have masked the effect of screening on mortality. They also reported that population mobility may have biased the findings.

The conclusion by Dr. Autier and colleagues that the 37% decline in breast cancer mortality in Sweden was not tied to breast cancer screening seems therefore hard to defend and partially unsupported by data (two groups of Swedish Counties do show a mortality decrease that, according to the stated criteria, could be tied to screening). They also feel, “it is time to move beyond an apparently never-ending debate on at what extent screening for breast cancer in itself conducted in the seventies through the nineties of the last century has reduced mortality for breast cancer, as if it was isolated from the rest of healthcare [...].The presence of an organized screening program may have promoted the provision of more effective care by monitoring the treatment quality of screen-detected cancers and by favoring the creation of multidisciplinary units of breast cancer specialists.”

In an accompanying editorial, Michael W. Vannier, MD, from the department of radiology at the University of Chicago Medical Center (IL, USA), noted that it is hard to see mortality decrease as a screening benefit because outliers such as the natural history of the disease, along with the frequency of screening as well as the duration of follow up may misrepresent the time patterns in the mortality reductions. “We know that isolating screening as an evaluable entity using death records fails to reveal major benefits,” he wrote, adding that even if screening were 100% effective, the number of deaths may remain unchanged. However, he feels that without a better option, mammography screening will continue to be utilized. “As our tools improve, we can begin to fully realize the promise of breast cancer screening to arrest this dread disease at its earliest stage with the least morbidity and cost.”

Related Links:
International Prevention Research Institute